These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28696690)

  • 21. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Back from ASCO 2019: Advances on NTRK inhibitors in childhood tumors].
    Doz F
    Bull Cancer; 2019; 106(7-8):615-616. PubMed ID: 31272686
    [No Abstract]   [Full Text] [Related]  

  • 23. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one.
    Bernard-Gauthier V; Boudjemeline M; Rosa-Neto P; Thiel A; Schirrmacher R
    Bioorg Med Chem; 2013 Dec; 21(24):7816-29. PubMed ID: 24183588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
    Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
    Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
    Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
    J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loxo TRK inhibitor data wows oncologists.
    Dolgin E
    Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
    [No Abstract]   [Full Text] [Related]  

  • 29. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
    Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
    J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease.
    Cai L; Liow JS; Zoghbi SS; Cuevas J; Baetas C; Hong J; Shetty HU; Seneca NM; Brown AK; Gladding R; Temme SS; Herman MM; Innis RB; Pike VW
    J Med Chem; 2008 Jan; 51(1):148-58. PubMed ID: 18078311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T; Yu D; Lamb ML
    Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal Structures of Neurotrophin Receptors Kinase Domain.
    Bertrand T
    Vitam Horm; 2017; 104():1-18. PubMed ID: 28215291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [
    Krishnan HS; Bernard-Gauthier V; Placzek MS; Dahl K; Narayanaswami V; Livni E; Chen Z; Yang J; Collier TL; Ran C; Hooker JM; Liang SH; Vasdev N
    Mol Pharm; 2018 Feb; 15(2):695-702. PubMed ID: 29298483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
    Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹C]MPPO) Based on α-Ketoheterocyclic Scaffold.
    Wang L; Yui J; Wang Q; Zhang Y; Mori W; Shimoda Y; Fujinaga M; Kumata K; Yamasaki T; Hatori A; Rotstein BH; Collier TL; Ran C; Vasdev N; Zhang MR; Liang SH
    ACS Chem Neurosci; 2016 Jan; 7(1):109-18. PubMed ID: 26505525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.